Background: Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with or without bevacizumab.

הקליקו כאן למחקר ב​- New England Journal of Medicine

N Engl J Med 2021; 385:1856-1867​